FOLH1 and anemia: Interestingly, Baum et al. [44] reported no hematotoxicity of 177Lu-DOTAGA-PSMA complex in patients with prostate cancer with no worsening of anemia and leukocytopenia after therapy and no grade three or four hematologic toxicity in any of the patients.